Table 1

DAVF patients treated with n-BCA

Case	Age/sex	Location	Cognard	Embolization occl	Surg occl	Complication
1	50–59/M	R Tr-Sig	IV	−	+
2	70–79/M	L Tr-Sig	IV	−^†	+	Tr vis. P.O.
3	60–69/M	R Trans	IV	−	+
4	70–79/M	L Sph-Par	IV	−	+
5	80–89/F	L Sig	IV	−	−	Death, stroke
6	60–69/F	L Tent	III	+	−
7	50–59/F	L Trans	IV	+	−	PE
8	70–79/M	L Tent	V	−	+
9	70–79/F	R Inf Petr	IV	+	−	Dissection
10	40–49/M	R Tr-Sig	IV	+	−
11	60–69/M	R Sag	IV	+	−	Dissection
12	60–69/M	L Trans	IV	+	−
13	70–79/F	R Sph-Par	IV	−	+
14	40–49/M	R Trans	IIa+b	−	+	SThr, stroke, Sz
15	30–39/M	Falx-BVR	IV	−	+
16	50–59/M	Sag	III	−	−	ACA perf x 2
17	80–89/M	L Trans	IV	−^*	−
18	40–49/M	F Mag vv	IV	+	−
19	50–59/M	L Trans	IV	−	+
20	40–49/M	L Trans	IV	−	+	PE
21	40–49/M	R Trans	IV	−	+

↵* n-BCA arterial and coils venous sinus.
↵† New fistula at edge of craniotomy site at 2 years.
ACA perf x 2, anterior cerebral artery perforation x 2; BVR, basal vein of Rosenthal; DAVF, dural arteriovenous fistula; F Mag, foramen magnum; n-BCA, n-butyl-2-cyanoacrylate PE, pulmonary embolus; Sig, sigmoid sinus; Sph-Par, spenoparietal sinus; SThr, sinus thrombosis; Sz, seizure; Tent, tentorium; Tr or Trans, transverse sinus; Tr vis. P.O., transient visual change post-op.